STAT Plus: Novartis faces another crisis. And for CEO Vas Narasimhan, this time is different
ALISSA AMBROSE/STAT
The revelation that Novartis’ gene therapy division filed falsified data to the FDA is at the very least a blemish on its CEO. It may be a bigger crisis.
No hay comentarios:
Publicar un comentario